Literature DB >> 20054283

Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease.

Moon Jae Chung1, Jae Hee Cheon, Seung Up Kim, Jae Jun Park, Tae Il Kim, Nam Kyu Kim, Won Ho Kim.   

Abstract

BACKGROUND: The aims of this study were to evaluate the efficacy of medical treatments and to identify factors to predict clinical outcome of intestinal Behçet disease (BD) during medical treatment.
METHODS: We performed a retrospective review of the medical records of 93 patients who were diagnosed and medically treated with intestinal BD at Severance Hospital, Seoul, Korea from 1992 to 2007. A therapeutic response was evaluated 8 weeks after the initiation of medical treatment, and cumulative recurrence and surgery rates were also assessed during long-term follow-up.
RESULTS: The initial remission rate at 8 weeks after treatment was 66.7%. During the follow-up period, cumulative recurrence rates for intestinal BD were 24.9% at 2 years and 43.0% at 5 years. The recurrence rate was significantly higher in patients with apparent gastrointestinal symptoms at their initial presentation, volcano-type and deep intestinal ulcers, and those who failed to achieve complete remission during the initial treatment. Cumulative rates for surgery were 6.7% at 2 years and 15.1% at 5 years. The typical type of ulcers was the only predictive factor for the likelihood of surgery.
CONCLUSIONS: Our study demonstrates that a considerable number of patients experience disease relapse during follow-up despite a high-remission rate after medical treatment for intestinal BD. Careful observation and intensive treatment should be carried out, especially in patients without complete remission after initial treatment, with deep and volcano-shaped ulcers, or with apparent gastrointestinal symptoms at the time of diagnosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20054283     DOI: 10.1097/MCG.0b013e3181c8a50f

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  10 in total

1.  Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behçet's disease.

Authors:  Jihye Park; Jae Hee Cheon; Yong Eun Park; Yoon Jee Lee; Hyun Jung Lee; Soo Jung Park; Sung Pil Hong; Tae Il Kim; Won Ho Kim
Journal:  Int J Colorectal Dis       Date:  2016-12-06       Impact factor: 2.571

Review 2.  Gastrointestinal Behçet's disease: a review.

Authors:  Wasseem Skef; Matthew J Hamilton; Thurayya Arayssi
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 3.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

Review 4.  Update on the Medical Management of Gastrointestinal Behçet's Disease.

Authors:  Giuseppe Lopalco; Donato Rigante; Vincenzo Venerito; Claudia Fabiani; Rossella Franceschini; Michele Barone; Giovanni Lapadula; Mauro Galeazzi; Bruno Frediani; Florenzo Iannone; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2017-01-22       Impact factor: 4.711

5.  C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet's disease.

Authors:  Eun Ae Kang; Jung Won Park; Min Soo Cho; Jae Hee Cheon; Yehyun Park; Soo Jung Park; Tae Il Kim; Won Ho Kim
Journal:  BMC Gastroenterol       Date:  2021-10-07       Impact factor: 3.067

Review 6.  Outcome predictors for intestinal Behçet's disease.

Authors:  Jae Jun Park; Won Ho Kim; Jae Hee Cheon
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

Review 7.  Intestinal Behçet's Disease: A True Inflammatory Bowel Disease or Merely an Intestinal Complication of Systemic Vasculitis?

Authors:  Duk Hwan Kim; Jae Hee Cheon
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

Review 8.  Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease.

Authors:  Tadakazu Hisamatsu; Mari Hayashida
Journal:  Intest Res       Date:  2017-06-12

9.  Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial.

Authors:  Nagamu Inoue; Kiyonori Kobayashi; Makoto Naganuma; Fumihito Hirai; Morio Ozawa; Dilek Arikan; Bidan Huang; Anne M Robinson; Roopal B Thakkar; Toshifumi Hibi
Journal:  Intest Res       Date:  2017-06-12

10.  Development of a Novel Endoscopic Scoring System to Predict Relapse after Surgery in Intestinal Behçet's Disease.

Authors:  Jung Won Park; Yehyun Park; Soo Jung Park; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Gut Liver       Date:  2018-11-15       Impact factor: 4.519

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.